Drug intelligence / Profile preview

Apiclof

Development stage: Unknown
Lead developer: Amman Pharmaceutical Industries
Modality: Small Molecules
Administration: Ophthalmic

Overview

Apiclof is a small molecule nonsteroidal anti-inflammatory drug (NSAID) formulated as 0.1% diclofenac sodium ophthalmic eye drops. Developed and marketed by Amman Pharmaceutical Industries, it functions by inhibiting the cyclooxygenase (COX-1 and COX-2) enzymes, which are responsible for the synthesis of prostaglandins that mediate pain and inflammation. The product is primarily indicated for the management of ocular pain and inflammation, specifically for injuries resulting from industrial welding (glare and burns), as well as for the reduction of post-operative inflammation following ophthalmic surgical procedures.

Brand names: Apiclof
Other names: diclofenac sodium 0.1% eye drops

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Apiclof.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apiclof.

Explore the full profile